Research, Innovation, Patient care / 19.03.2026
Strengthen international cooperation in clinical trials

As part of the Australian Clinical Trials Initiative, ACTI, Australian companies and representatives of the Australien Government’s Trade and Invest Commission, Austrade, visited the Berlin-Buch Science and Biotech Campus today. The initiative promotes Australia as an attractive location for clinical trials.

Dr. Christina Quensel, CEO der Campus Berlin-Buch GmbH, welcomed the guests and, during a tour, provided information about the campus’s ecosystem of basic biomedical and clinical research, life science startups, and biotechnology companies. Biotech and medtech companies operate here in one of Europe's leading biotech parks.

The delegation gained insight into two scientific core facilities the Proteomic Lab of the Berlin Institute of Health in the Charité und the Cryo Electron Microscopy, a collaborative scientific infrastructure involving Charité – Universitätsmedizin Berlin, the Max Delbrück Center, and the Leibniz Research Institute for Molecular Pharmacology.

At the BerlinBioCube startup center, the guests visited the startups CheckImmune GmbH, a CRO, and T-knife GmbH, a pharmaceutical company that develops highly innovative cancer therapies.

During a networking lunch, the delegation engaged in intensive discussions with executives and stakeholders of the BiotechPark Berlin-Buch.

Many thanks to our guests for the exciting exchange!

Minesh Lalla, Senior Business Development Manager at Peter MacCallum Cancer Centre (CTS)
Jason Erasmus, Business Development Manager at Beyond Drug Development (CRO)
Tim Vale, Business Development Manager at Resolian Bioanalytics (Lab)
Karl Boehle, Senior Business Development Manager, Austrade
Pallavi Mishra, South Australia Trade & Investment Manager, Austrade
Prime Financial Group (R&D Tax Advisors)
Bellberry (Ethics)

The delegation then proceeded to Berlin Partner for Technology and Business, which, in cooperation with Austrade, had hosted an exclusive seminar on opportunities for German-Australian collaboration in clinical trials. The event highlighted how the Australian clinical trial ecosystem is structured and the key strengths and efficiency advantages it offers. Executives were invited The event was aimed at pharmaceutical and biotech R&D leaders, clinical operations and trial strategy decision-makers, CROs and clinical service providers, as well as leaders from academic, hospital, and research institutions, and stakeholders in policy, innovation, and the ecosystem.